



Pan American
Health
Organization



World Health
Organization
Americas Region

PANAFTOSA

Pan American Center for Foot-and-Mouth
Disease and Veterinary Public Health

BIENNIAL PLAN 2026–2027

**FOR THE STRENGTHENING OF TECHNICAL COOPERATION
FROM PANAFTOSA TOWARD THE CONSOLIDATION OF THE
HEMISPHERIC PROGRAM FOR THE ERADICATION OF
FOOT-AND-MOUTH DISEASE (PHEFA)**

April 2026

STRENGTHENING OF PANAFTOSA TECHNICAL COOPERATION TOWARDS THE CONSOLIDATION OF THE PHEFA

It is recognized that the coordination and technical cooperation provided by PANAFTOSA/PAHO, within the framework of the Hemispheric Program for the Eradication of Foot-and-Mouth Disease (PHEFA), has been fundamental to the progress achieved to date. These efforts remain essential to achieving the complete eradication of Foot-and-Mouth Disease (FMD) in the continent, without compromising the gains already made.

In 2025, the Region reached its best historical record in terms of areas recognized as free of FMD by the World Organisation for Animal Health (WOAH). This progress has been reflected in a significant increase in disease-free zones without vaccination, marking an important milestone in the eradication process.

In this context, countries have begun implementing the new PHEFA Action Plan 2026–2030, whose main objective is to complete the eradication of FMD, particularly in Venezuela, which remains the main focus of the final phase. For countries that are already disease-free, the approach focuses on strengthening biosecurity, prevention, and emergency response capacity.

The financing of PANAFTOSA/PAHO technical cooperation for PHEFA is organized through PAHO contributions, which includes the allocation of international professionals specialized in FMD and in the Reference Laboratory, as well as experts in cross-cutting areas such as epidemiology. In addition, resources are generated from the supply of reference materials to countries, and through a model of voluntary contributions linked to specific national and regional projects, the latter contributing to the PAHO PHEFA Fund. These elements are reflected in the costs of the Biennial Plan 2026–2027.

The expected results of the plan will contribute directly to the goals established in the PHEFA Action Plan 2026–2030, aligning with the priorities of PANAFTOSA/PAHO and the resolutions of COSALFA. These actions are aimed at preparing countries for the final phase of eradication and ensuring the sustainability of the achievements obtained.

In accordance with these guidelines and considering the current situation, PANAFTOSA/PAHO has developed the proposal for the Biennial Technical Cooperation Plan 2026–2027, with the objective of consolidating the progress achieved under PHEFA and achieving the definitive eradication of FMD across the continent.

LOGICAL FRAMEWORK MATRIX

	INDICATORS	VERIFICATION METHODS	ASSUMPTIONS EXTERNAL TO THE PROJECT
<p>Goal: PHEFA consolidated to address the final stage of FMD eradication in the continent.</p>	<p>100% of countries have strengthened programs under implementation, with resources allocated for the eradication of FMD, with emphasis on priority countries and areas.</p>	<p>Ad hoc evaluations</p>	<p>Countries have made political decisions, allocated resources and implemented national plans aligned with PHEFA.</p> <p>The region has a fund and human and financial resources to support actions in the countries.</p>
<p>Purpose: Ensure the effectiveness, coordination, support, and monitoring of PHEFA and the adoption of its actions in the countries.</p>	<p>All COSALFA member countries meet the PHEFA targets for the period (2026–2027) with effective technical cooperation from PANAFTOSA/PAHO.</p>	<p>PANAFTOSA/PAHO reports COSALFA reports Country reports</p>	<p>Agreements reached.</p> <p>National and local authorities and stakeholders adhere to and comply with the commitments established in PHEFA.</p> <p>PANAFTOSA/PAHO has the capacity to meet expectations.</p>

EXPECTED OUTCOMES	INDICATORS	VERIFICATION METHODS	ASSUMPTIONS
EO1: Processes from transitioning to the FMD free status	<ol style="list-style-type: none"> 1. Transition processes of countries from FMD-free with vaccination are underway, following the recommendations of the PANAFTOSA/PAHO Technical Guidelines and the PHEFA Action Plan 2026–2030. 2. Countries and zones are supported by PANAFTOSA/PAHO during the transition process. 	PANAFTOSA/PAHO Technical Mission reports and country situation reports sent to the COSALFA.	<ul style="list-style-type: none"> • Countries make decisions for the transition toward FMD-free status without vaccination.
EO2: Strengthening and support of national programs	<ol style="list-style-type: none"> 1. Monitoring and strengthening of the Technical Cooperation Program with Venezuela, with support from countries in the region and PANAFTOSA/PAHO. 2. National FMD Diagnostic Laboratories in countries supported by the PANAFTOSA/PAHO Reference Laboratory. 3. Demand for kits for the diagnosis of vesicular diseases, FMD vaccine control, and transmission and immunity studies attended by the PANAFTOSA/PAHO Laboratory. 	PANAFTOSA/PAHO reports and country reports submitted to COSALFA.	<ul style="list-style-type: none"> • The Government of Venezuela recognizes FMD eradication as a priority, allocates resources to strengthen the Official Veterinary Service, and accepts technical cooperation from countries and PANAFTOSA/PAHO. • The countries contribute to the funding of PANAFTOSA/PAHO technical cooperation and participate actively of the actions in Venezuela. • Countries provide financial support for prevention, surveillance, and control activities of FMD programs.
EO3: Strengthening of surveillance systems and risk analysis of country programs	<ol style="list-style-type: none"> 1. All countries timely report the occurrence of FMD to WOA and PANAFTOSA/PAHO and submit the information required by COSALFA. 2. Countries conduct surveillance activities to verify absence of infection/transmission with support from PANAFTOSA/PAHO. 3. Countries perform FMD risk analysis using harmonized methodologies supported by PANAFTOSA/PAHO. 	<p>WOAH reports and WAHIS system data.</p> <p>COSALFA reports.</p> <p>Published studies.</p>	<ul style="list-style-type: none"> • Countries report in a timely manner to WOA and submit information to PANAFTOSA/PAHO. • Veterinary Services have sufficient funding to conduct surveillance activities and risk analysis studies.

<p>EO4: Development of new tools and studies by PANAFTOSA</p>	<ol style="list-style-type: none"> 1. Modeling studies provided by PANAFTOSA/PAHO and available for use by countries. 2. New laboratory diagnostic methods developed and validated with countries. 3. Production of reference materials. 4. Studies conducted on experimental vaccine potency and field immunity dynamics. 	<p>Reports and training activities coordinated by PANAFTOSA/PAHO.</p> <p>Published studies.</p> <p>Reports from the PANAFTOSA/PAHO Reference Laboratory.</p>	<p>Continuity of specialized technical teams in countries and within PANAFTOSA/PAHO.</p>
<p>EO5: Maintenance of the Regional Bank of Vaccines and Antigens for Foot-and-Mouth Disease</p>	<ol style="list-style-type: none"> 1. Antigen/Vaccine Bank operational. 	<p>Constitutive Agreement signed by participating countries.</p> <p>Procurement contracts for FMD antigens/vaccines signed with suppliers.</p>	<p>Countries contribute financial resources for the maintenance of BANVACO.</p>
<p>EO6: Implementation of the Regional Training and Professional Capacity-Building Plan</p>	<ol style="list-style-type: none"> 1. Training needs identified and aligned with the current phase of countries to address PHEFA demands. 2. Strengthened emergency response capacities of countries through updated contingency plans and FMD training. 	<p>Participant attendance lists from countries.</p> <p>Updated national contingency plans.</p> <p>Published training plans.</p>	<p>Countries have defined their training priorities and updated contingency plans and have allocated resources for their implementation.</p>

ANNEX 1
COST SPREADSHEET

EXPECTED OUTCOMES	ACTIVITIES	COST PER ACTIVITY YEAR 2026 (US\$)	COST PER ACTIVITY YEAR 2027 (US\$)	TOTAL COST (US\$)
EO1: Support to the countries in the transition processes to the FMD free status	1. Support in the development of roadmaps for the transition from FMD-free with vaccination to FMD-free without vaccination, following PANAFTOSA/PAHO Technical Guidelines.	5.000	5.000	30.000
	2. PANAFTOSA/PAHO support to countries during the transition process.	10.000	10.000	
EO2: Support and strengthening of national programs	3. Monitoring and strengthening of the Technical Cooperation Program with Venezuela, with the support of countries in the region and PANAFTOSA/PAHO.	500.000	1.000.000	1.760.000
	4. FMD diagnostic laboratories in countries supported by the PANAFTOSA/PAHO Reference Laboratory.	20.000	40.000	
	5. Demand for kits for the diagnosis of vesicular diseases, vaccine control, and transmission and immunity studies, addressed by the PANAFTOSA/PAHO Laboratory.	100.000	100.000	
EO3: Strengthening of surveillance systems and risk analysis of country programs	6. Countries timely report FMD occurrence to WOAHP and submit required information to COSALFA.	0	0	60.000
	7. Countries carry out surveillance actions to verify absence of infection/transmission and are supported by PANAFTOSA/PAHO.	10.000	10.000	
	8. Countries conduct FMD risk analysis using harmonized methodology supported by PANAFTOSA/PAHO.	20.000	20.000	

EO4: Development of new tools and studies by PANAFTOSA	9. Countries conduct modelling studies supported by PANAFTOSA/PAHO	15.000	15.000	250.000
	10. New laboratory diagnostic methods developed and validated with countries.	5.000	15.000	
	11. Production of reference materials	50.000	50.000	
	12. Conduct of studies on experimental vaccine potency and field immunity dynamics.	50.000	50.000	
EO5: Maintenance of the Regional Bank of Vaccines and Antigens for FMD	13. BANVACO operational	75.000	75.000	150.000
EO6: Implementation of the Regional Training and Capacity-Building Plan.	14. Development and implementation of training plans (laboratory and field) adapted to the current phase of countries under PHEFA	90.000	90.000	280.000
	15. Support for the review and updating of contingency plans, including laboratory components, for FMD in COSALFA countries	50.000	50.000	
TOTAL		1.000.000	1.530.000	2.530.000